Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Cell Therapy Manufacturing Automation Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The cell therapy manufacturing market has experienced rapid expansion in recent years. It is projected to grow from $1.81 billion in 2025 to $2.08 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.8%. The historical growth of this market can be attributed to the rising demand for cell processing, the increasing requirements for manufacturing scalability, the growing adoption of automated bioreactors, the expansion of GMP-compliant workflows, and a heightened focus on achieving production consistency.
The cell therapy manufacturing market size is anticipated to undergo substantial growth in the upcoming years. It is projected to expand to $3.58 billion in 2030, with a compound annual growth rate (CAGR) of 14.5%. This expected growth over the forecast period stems from factors such as increasing volumes of personalized therapies, augmented investment in automation platforms, a rising imperative for contamination-free workflows, the broadening of large-scale commercial manufacturing, and more rigorous regulatory quality demands. Key trends during this period are expected to include technological progress in closed systems, process innovations driven by automation, the evolution of integrated workflows, research into real-time analytics, and advancements in robotics research and development.
Get A Free Sample Report With In-Depth Market Insights:
Cell Therapy Manufacturing Automation Market Demand Drivers Opening New Revenue Streams
The expanding need for gene therapies is projected to fuel the advancement of the cell therapy manufacturing automation market moving ahead. Gene therapy constitutes a medical method centered on altering or substituting faulty genes to address or avert illnesses. This heightened demand for gene therapy arises from progress in genetic sequencing and diagnostics, which permit accurate identification of disease-causing genes for focused intervention. Cell therapy manufacturing automation assists gene therapy by optimizing and regularizing intricate production procedures, thereby guaranteeing uniform quality and potential for scaling. It improves therapeutic progress by lessening errors, enhancing operational effectiveness, and enabling dependable large-scale production of gene-modified cells. For instance, in December 2024, as per the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) authorized six gene therapy products in 2023, an increase from five approvals in 2022. Consequently, the increasing requirement for gene therapies is propelling the expansion of the cell therapy manufacturing automation market.
Cell Therapy Manufacturing Automation Market Segment Landscape And Growth Outlook
The cell therapy manufacturing automation market covered in this report is segmented –
1) By Component: Hardware, Software, Services
2) By Cell Type: T-Cells, Stem Cells, Natural Killer (NK) Cells, Other Cell Types
3) By Process: Upstream Processing, Downstream Processing, Fill-Finish, Quality Control, Other Processes
4) By End-User: Pharmaceutical And Biotechnology Companies, Research Institutes, Contract Manufacturing Organizations (CMOs), Other End-Users
Subsegments:
1) By Hardware: Automated Bioreactor Systems, Robotic Handling Platforms, Automated Separation Devices, Automated Expansion Units, In Line Quality Analyzers
2) By Software: Electronic Batch Record Software, Manufacturing Execution Software, Workflow Management Software, Data Monitoring Software, Compliance Management Software
3) By Services: Installation Services, Maintenance Services, Validation Services, Training Services, Technical Support Services
Cell Therapy Manufacturing Automation Market Trends Powering Strategic Industry Growth
Leading companies within the cell therapy manufacturing automation market are concentrating on creating sophisticated solutions, like automated cell therapy systems, aimed at integrating multi-stage manufacturing workflows into unified, validated digital frameworks that minimize manual interventions and bolster regulatory compliance. An automated cell therapy system is defined as an off-the-shelf validated automation solution which digitally links various cell therapy instruments (for example, magnetic separation, centrifugation, electroporation, and incubators) into a unified interface, thereby ensuring traceability, repeatability, and cGMP compliance throughout all production stages. As an example, in January 2024, the US-based life sciences company Thermo Fisher Scientific Inc. introduced Gibco CTS Cellmation Software, an innovative automation solution. This unique, off-the-shelf validated software solution digitally connects instruments across Thermo Fisher’s cell therapy portfolio to automate manufacturing workflows. It incorporates a pre-validated automation system, driven by Emerson’s DeltaV technology, facilitating the seamless integration and control of numerous instruments without requiring expensive custom projects. Furthermore, it establishes traceable and repeatable workflows that aid in ensuring adherence to cGMP and data security regulations, ultimately diminishing manual efforts for ground therapy developers.
Cell Therapy Manufacturing Automation Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the cell therapy manufacturing automation market are Thermo Fisher Scientific Inc., Merck KGaA, Fujifilm Holdings Corporation, Corning Incorporated, Lonza Group AG, Cytiva, WuXi AppTecCo. Ltd., Hitachi High Technologies Corp., CatalentInc., Sartorius AG, Beckman Coulter Life Sciences, Terumo BCT Inc., Miltenyi Biotec, Oxford Biomedica Plc, National Resilience LLC, Minaris Regenerative Medicine LLC, Tulip Interfaces Inc., Invetech Pty Ltd., BlueRock Therapeutics LLC, Cellares Inc., Ascential Medical & Life Sciences, Cell and Gene Therapy Catapult
View The Full Cell Therapy Manufacturing Automation Market Report:
Cell Therapy Manufacturing Automation Market Geographic Distribution And Regional Opportunities
North America was the largest region in the cell therapy manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy manufacturing automation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
